Drug Profile
Research programme: osteoarthritis therapy - AstraZeneca
Alternative Names: AZD-6357; AZD-6605Latest Information Update: 14 Feb 2008
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 07 Dec 2007 Discontinued - Preclinical for Osteoarthritis in United Kingdom (unspecified route)
- 04 Jul 2006 This programme is still in active development
- 04 Aug 2004 Preclinical trials in Osteoarthritis (unspecified route)